




From cytology based to HPV based screening

	Untill 2016	2017
Age (years)	30 - 60	30 - 60 (65 HPV+)
Method	Clinical sample GP	Clinical sample GP Selfsampling non- responders
Test	Cytology	HPV HPV+/Cytology
Follow-up 6 month	ASCUS/LSIL	HPV+
Referral Gynaecologist	HSIL>	HPV+ and ASCUS>




hrHPV testing






Cytology triage testing






Follow-up smear





Self-sampling






Results

	2016	2017
referral rate total	1.9%	3.6%
referral rate direct	0.93%	2.60%
referral rate indirect	0.79%	1.00%
followed referral total	91%	75%
followed referral direct	91%	77%
followed referral indirect	76%	69%
detection screening programme		
total	0.99%	1.25%
detection screening programme		
direct	0.69%	1.00%
detection screening programme		
indirect	0.27%	0.25%
PVV total	56.3%	34.7%
PVV direct	71.5%	38.4%
PVV indirect	7.2%	4.7%



Framework



Advise CvB **Program committee**consisting of

representatives of

professionals

Advice Program committee **Workgroups**



Renewed programme: Phases

Decisionmaking phase (2 years)

Preparation phase (3,5 years)

- Tenders; HPV, selfsampling, labs
- Organisation screenlaboratories
- Set up information technologies
- Framework tasks and responsibilities professionals
- Guidelines GP, pathology, gynecology
- Development communication and education materials

Implementation phase (8 months)

- Set up and testing laboratories (testing with old samples)
- First lab testing IT and workflow low volume (2.000)
- Education of professionals (HPV/cytology)


Transition




Transition

2016 stop cytology screeningprogram

- Concentration of invitations before september
- Recall in september
- Informing clients that cytology screening stops
- Informing GP to stop taking smears in december
- Labs could finish cytology in january
- Old IT system closed on 20th of january
- Migration of data on 21th of january in new IT system



letter and folder; basic information





What can the results be?

About four weeks after the screening, you will receive a letter with the results. You can get the following results:

No HPV

You do not have an increased risk of cervical cancer. Further testing is not necessary. You may participate in the screening again in the next round of invitations.



91 out of 100 women get this result.

HPV detected, no abnormal cells You will receive another invitation for a smear test at the family doctor after six months. We then check once again to ensure that no abnormal cells are present.



5 out of 100 women get this result.

HPV and abnormal cells detected

Further examination by a gynaecologist is necessary. He/She will decide whether treatment is necessary.



2 out of 100 women get this result

Unclose

A new smear test is required. Please make an appointment with your family doctor for this in about six weeks after your first smear test.

In 2 out of 100 women, the smear test is inconclusive.



QA in primary hrHPV screening

Characteristics 1st hrHPV screening programme

- Five test sites representing five different regions
- All test sites similar hrHPV test equipment
- Two sample flows (clinical samples, self samples)
 - Large daily throughput, each lab 450 samples daily
 - Low prevalence
 - → fast adjustments if required
- Specific attention to QA in primary hrHPV screening
 - Performance over time
 - Performance in different regions
 - Performance in relation to other testsystems





HUISARTS



QA in traige cytology screening

Characteristics 1st hrHPV screening programme

- Increased abnormal cytology
- HPV-bias (influence of knowledge HPV on cytology)
- Increased referral



- Specific attention to QA in triage cytology screening
 - Instructions and learning effect HPV-bias
 - Referrals over time
 - Referrals in different regions







Continuous process of optimizations

- Investigating possibilities to decrease unnecessary referrals, for example by adding genotyping to our triage (2022)
- Stronger position self-sampling, by sending them out to nonresponders and all first-invited-women (2023)
- Preparing for HPVvaccinated women in screening program (2023)
- Lowering barriers for participation (2021)
- Dealing with consequences of the COVID19-pandemic













HEDERLANDSE VERENIGING VOOR















Universitair Medisch Centrum Groningen











More?

Website:

www.rivm.nl/en/topics

Feasibility report (organization, finances, support)
Framework new screening
Folders for the participants

Sandra.van.Dijk@rivm.nl